Spyre Therapeutics, Inc. SYRE Less than 12 months
Less than 12 months at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s less than 12 months.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s less than 12 months?
- Spyre Therapeutics, Inc. (SYRE) reported less than 12 months of $432M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s less than 12 months changed year-over-year?
- Spyre Therapeutics, Inc.'s less than 12 months increased by 310.8% year-over-year, from $105.15M to $432M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s less than 12 months?
- Over 3 years (2022 to 2025), Spyre Therapeutics, Inc.'s less than 12 months has grown at a 93.0% compound annual growth rate (CAGR), from $25.17M to $180.96M.